G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) - Pipeline Review, H1 2016

  • ID: 3802807
  • Report
  • 34 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Ardelyx, Inc.
  • Venenum Biodesign
  • MORE
G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) - Pipeline Review, H1 2016

Summary

‘G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) - Pipeline Review, H1 2016’, provides in depth analysis on G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) targeted pipeline therapeutics.

The report provides comprehensive information on the G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1)
- The report reviews G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Ardelyx, Inc.
  • Venenum Biodesign
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) Overview

Therapeutics Development

G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) - Products under Development by Stage of Development

G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) - Products under Development by Therapy Area

G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) - Products under Development by Indication

G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) - Pipeline Products Glance

Early Stage Products

G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) - Products under Development by Companies

G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) - Products under Development by Universities/Institutes

G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) - Companies Involved in Therapeutics Development

Ardelyx, Inc.

Intercept Pharmaceuticals, Inc.

Torrent Pharmaceuticals Limited

Venenum Biodesign

G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) - Drug Profiles

Drug to Agonize TGR-5 for Type 2 Diabetes and Metabolic Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INT-767 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INT-777 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RDX-98940 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-0071261 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize TGR5 Receptor for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRC-210258 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) - Dormant Projects

G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) - Discontinued Products

G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) - Featured News & Press Releases

Nov 30, 2015: Intercept Pharmaceuticals Initiates Phase 1 Study of INT-767, a Dual FXR and TGR5 Agonist

Apr 13, 2010: Intercept To Present Data On Dual FXR/TGR5 Agonist INT-767 At EASL 2010

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 34List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Ardelyx, Inc., H1 2016

Pipeline by Intercept Pharmaceuticals, Inc., H1 2016

Pipeline by Torrent Pharmaceuticals Limited, H1 2016

Pipeline by Venenum Biodesign, H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 31List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Ardelyx, Inc.
  • Venenum Biodesign
  • MORE
According to the author's, recently published report 'G-Protein Coupled Bile Acid Receptor 1 - Pipeline Review, H1 2016'; G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the author says; G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) G protein-coupled bile acid receptor 1 (GPBAR1) is a protein encoded by the GPBAR1 gene. It is a receptor for bile acid. Bile acid-binding induces its internalization, activation of extracellular signal-regulated kinase and intracellular cAMP production. It is involved in the suppression of macrophage functions by bile acids.

The report 'G-Protein Coupled Bile Acid Receptor 1 - Pipeline Review, H1 2016' outlays comprehensive information on the G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in G-Protein Coupled Bile Acid Receptor 1 (G-Protein Coupled Receptor GPCR19 or Membrane-Type Receptor For Bile Acids or M-BAR or hBG37 or BG37 or TGR5 or GPR131 or GPBAR1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase I and Preclinical stages are 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 5
Ardelyx, Inc.
Intercept Pharmaceuticals, Inc.
Torrent Pharmaceuticals Limited
Venenum Biodesign
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll